Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.94 -2.33% -0.07
CDTX closed down 2.33 percent on Friday, January 18, 2019, on 41 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CDTX trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.33%
Jan 17 MACD Bullish Centerline Cross Bullish -2.33%
Jan 17 Narrow Range Bar Range Contraction -2.33%
Jan 17 NR7 Range Contraction -2.33%
Jan 17 Inside Day Range Contraction -2.33%
Jan 17 Wide Bands Range Expansion -2.33%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.97%

Older signals for CDTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Is CDTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.55
52 Week Low 1.94
Average Volume 127,501
200-Day Moving Average 4.1582
50-Day Moving Average 3.159
20-Day Moving Average 2.7185
10-Day Moving Average 3.027
Average True Range 0.3012
ADX 22.27
+DI 15.8305
-DI 13.5497
Chandelier Exit (Long, 3 ATRs ) 2.3964
Chandelier Exit (Short, 3 ATRs ) 2.8436
Upper Bollinger Band 3.4747
Lower Bollinger Band 1.9623
Percent B (%b) 0.65
BandWidth 55.633621
MACD Line 0.0021
MACD Signal Line -0.0568
MACD Histogram 0.0589
Fundamentals Value
Market Cap 49.58 Million
Num Shares 16.9 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -0.83
Price-to-Sales 0.00
Price-to-Book 2.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.09
Resistance 3 (R3) 3.10 3.06 3.07
Resistance 2 (R2) 3.06 3.02 3.06 3.06
Resistance 1 (R1) 3.00 3.00 2.98 2.99 3.05
Pivot Point 2.96 2.96 2.95 2.96 2.96
Support 1 (S1) 2.90 2.92 2.88 2.89 2.83
Support 2 (S2) 2.86 2.90 2.86 2.82
Support 3 (S3) 2.80 2.86 2.82
Support 4 (S4) 2.79